Waldencast plc (WALD)
시가총액: 369.39M
국가: United States
산업: #Package_Goods_Cosmetics
섹터: #Consumer_Discretionary
홈페이지: https://www.waldencast.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 65.44M / 68.34M / -4.2% / -- / --
2412: -- / 70.77M / -- / -- / --
2409: 70.2M / 68.88M / 1.9% / -- / 10.9%
2406: 63.31M / 58.3M / 8.6% / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.07 / -0.038 / -84.2% / -- / --
2412: -- / -0.0524 / -- / -- / --
2409: -0.05 / -0.05 / 0.0% / -- / -25.0%
2406: -0.04 / -0.03 / -33.3% / -- / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 218.14M(--) / --(--)
2112: 142.47M(50.9%) / -2.45(-1107.3%)
2012: 94.43M(--) / -0.202939(--)

#WALD

- 사업요약: Waldencast plc operates in the beauty and wellness industry. It engages in developing, acquiring, accelerating, and scaling various brands. The company offers skincare products that are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage through the medical, spa, and retail channels. It also prov...

Olema Pharmaceuticals, Inc. (OLMA)
시가총액: 319.93M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://olema.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: 0.00 / 0.00 / -- / -- / --
2406: 0.00 / 0.00 / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.36 / -0.54 / 33.3% / 35.7% / 29.4%
2412: -0.51 / -0.64 / 20.3% / -- / 15.0%
2409: -0.6 / -0.5754 / -4.3% / -25.0% / -11.1%
2406: -0.54 / -0.5431 / 0.6% / -10.2% / 3.6%
2403: -0.56 / -- / -- / 20.0% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / --(--)
2212: 0.0(--) / -2.62(-45.6%)
2112: 0.0(--) / -1.8(47.4%)
2012: 0.0(--) / -3.42(-1017.2%)

#OLMA

- 사업요약: Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER ...

Arteris, Inc. (AIP)
시가총액: 326.32M
국가: United States
산업: #Semiconductors
섹터: #Technology
홈페이지: https://www.arteris.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 16.53M / 15.69M / 5.4% / 27.7% / 6.6%
2412: 15.5M / 14.92M / 3.9% / 24.0% / 5.4%
2409: 14.7M / 14.72M / -0.1% / 10.7% / 0.7%
2406: 14.6M / 13.75M / 6.2% / -0.9% / 12.8%
2403: 12.95M / -- / -- / -1.6% / 3.5%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.09 / -0.0992 / 9.3% / 64.0% / 10.0%
2412: -0.1 / -0.14 / 28.6% / -- / -25.0%
2409: -0.08 / -0.12 / 33.3% / 65.2% / 27.3%
2406: -0.11 / -0.14 / 21.4% / 57.7% / 56.0%
2403: -0.25 / -- / -- / 3.8% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 53.67M(6.5%) / --(--)
2212: 50.38M(33.0%) / -0.84(20.8%)
2112: 37.86M(19.0%) / -1.06(-674.7%)
2012: 31.81M(--) / -0.136824(-165.3%)

#AIP

- 사업요약: Arteris, Inc. provides semiconductor system intellectual property solutions in the Americas, the Asia Pacific, Europe, and the Middle East. It manages on-chip communications and IP block deployments in System-on-Chip (SoC) se...

M-tron Industries, Inc. (MPTI)
시가총액: 167.1M
국가: United States
산업: #Industrial_Machinery_Components
섹터: #Technology
홈페이지: https://www.mtronpti.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 12.73M / 13M / -2.1% / 13.8% / -0.6%
2412: 12.81M / 12.6M / 1.7% / 18.9% / -3.0%
2409: 13.21M / 12.2M / 8.3% / 21.3% / 11.9%
2406: 11.81M / 11.2M / 5.4% / 16.5% / 5.6%
2403: 11.19M / -- / -- / 19.4% / 3.8%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.56 / 0.66 / -15.2% / 5.7% / -23.3%
2412: 0.73 / 0.56 / 30.4% / -- / -9.9%
2409: 0.81 / 0.54 / 50.0% / 42.1% / 28.6%
2406: 0.63 / 0.5 / 26.0% / 34.0% / 18.9%
2403: 0.53 / -- / -- / 165.0% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 41.17M(29.3%) / --(--)
2212: 31.84M(19.3%) / 0.67(128.3%)
2112: 26.69M(-11.0%) / 0.293481(-31.5%)
2012: 29.98M(--) / 0.428534(--)

#MPTI

- 사업요약: M-tron Industries, Inc. engages in the design, manufacture, and marketing of frequency and spectrum control products in the United States and internationally. The company's products include radio frequency, ...

DiaMedica Therapeutics Inc. (DMAC)
시가총액: 167.57M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.diamedica.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / 0.00 / -- / -- / --
2409: 0.00 / -- / -- / -- / --
2406: 0.00 / -- / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.18 / -0.2 / 10.0% / -28.6% / 0.0%
2412: -0.18 / -0.1725 / -4.3% / -- / -20.0%
2409: -0.15 / -0.16 / 6.2% / -25.0% / -15.4%
2406: -0.13 / -0.16 / 18.8% / 18.8% / 7.1%
2403: -0.14 / -- / -- / 30.0% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / -0.6(-15.4%)
2212: 0.0(--) / -0.52(20.0%)
2112: 0.0(--) / -0.65(16.7%)
2012: 0.0(--) / -0.78(--)

#DMAC

- 사업요약: DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of...

Fractyl Health, Inc. (GUTS)
시가총액: 83.75M
국가: United States
산업: None
섹터: None
홈페이지: https://fractyl.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -100.0% / -100.0%
2412: 3K / -- / -- / -57.1% / -78.6%
2409: 14K / -- / -- / -61.1% / -67.4%
2406: 43K / -- / -- / -40.3% / 30.3%
2403: 33.0K / -- / -- / 560.0% / 371.4%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.47 / -0.41 / -14.6% / -176.5% / 9.6%
2412: -0.52 / -0.42 / -23.8% / -- / -4.0%
2409: -0.5 / -- / -- / -- / -78.6%
2406: -0.28 / -- / -- / -- / -64.7%
2403: -0.17 / -- / -- / 49.9% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 120000.0(--) / -1.982457(-48.3%)
2212: 0.0(--) / -1.336626(-19.6%)
2112: 0.0(--) / -1.117919(-30.1%)
2012: 0.0(--) / -0.859156(--)

#GUTS

- 사업요약: Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic...

Hyperfine, Inc. (HYPR)
시가총액: 54.17M
국가: United States
산업: #Biotechnology_Electromedical_and_Electrotherapeutic_Apparatus
섹터: #Health_Care
홈페이지: https://hyperfine.io

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 2.14M / 2.89M / -26.0% / -35.1% / -7.8%
2412: 2.32M / 3.3M / -29.7% / -13.6% / -36.3%
2409: 3.64M / 3.3M / 10.3% / 56.2% / 0.3%
2406: 3.63M / 3.26M / 11.3% / 7.4% / 10.2%
2403: 3.29M / -- / -- / 25.0% / 22.7%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.12 / -0.1167 / -2.8% / 14.3% / 14.3%
2412: -0.14 / -0.14 / 0.0% / 6.7% / 0.0%
2409: -0.14 / -0.14 / 0.0% / 6.7% / 0.0%
2406: -0.14 / -0.1409 / 0.6% / 6.7% / 0.0%
2403: -0.14 / -- / -- / 17.6% / 6.7%

- 연간 매출(YoY%), EPS(YoY%)
2312: 11.03M(61.9%) / -0.62(40.4%)
2212: 6.81M(355.5%) / -1.04(94.1%)
2112: 1.5M(408.8%) / -17.57(-5152.3%)
2012: 294000.0(--) / -0.334517(--)

#HYPR

- 사업요약: Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States, Europe, and Middle Eastern Markets. The company offers...

Repare Therapeutics Inc. (RPTX)
시가총액: 60.58M
국가: Canada
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.reparerx.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 1.94M / -100.0% / -100.0% / -100.0%
2412: 2.65M / 2.73M / -2.9% / -79.7% / 130.4%
2409: 1.15M / 2.91M / -60.5% / -46.7% / 7.5%
2406: 1.07M / 2.58M / -58.5% / -96.5% / -98.0%
2403: 52.4M / -- / -- / 822.9% / 301.7%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.71 / -0.63 / -12.7% / -336.7% / -6.0%
2412: -0.67 / -0.81 / 17.3% / -- / 17.3%
2409: -0.81 / -0.87 / 6.9% / -80.0% / 1.2%
2406: -0.82 / -0.87 / 5.7% / -192.9% / -373.3%
2403: 0.3 / -- / -- / 136.1% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 51.13M(-61.2%) / --(--)
2212: 131.83M(1634.6%) / -0.69(75.6%)
2112: 7.6M(5529.6%) / -2.83(-6.4%)
2012: 135000.0(--) / -2.66(-126.7%)

#RPTX

- 사업요약: Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in...

Biodesix, Inc. (BDSX)
시가총액: 53.14M
국가: United States
산업: #Medical_Specialities
섹터: #Health_Care
홈페이지: https://www.biodesix.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 17.96M / 20.24M / -11.3% / 21.2% / -12.0%
2412: 20.42M / 19.87M / 2.8% / 39.2% / 12.2%
2409: 18.2M / 18.57M / -2.0% / 34.9% / 1.7%
2406: 17.9M / 16.12M / 11.0% / 50.8% / 20.8%
2403: 14.82M / -- / -- / 63.6% / 1.0%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.08 / -0.069 / -15.9% / 42.9% / -33.3%
2412: -0.06 / -0.07 / 14.3% / 40.0% / 14.3%
2409: -0.07 / -0.07 / 0.0% / 50.0% / 12.5%
2406: -0.08 / -0.09 / 11.1% / 52.9% / 42.9%
2403: -0.14 / -- / -- / 41.7% / -40.0%

- 연간 매출(YoY%), EPS(YoY%)
2312: 49.09M(28.5%) / --(--)
2212: 38.21M(-29.9%) / -1.55(1.9%)
2112: 54.51M(19.6%) / -1.58(75.6%)
2012: 45.56M(--) / -6.48(-864.0%)

#BDSX

- 사업요약: Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part ...

TransAct Technologies Incorporated (TACT)
시가총액: 35.89M
국가: United States
산업: #Computer_peripheral_equipment
섹터: #Technology
홈페이지: https://www.transact-tech.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 13.1M / 12.18M / 7.6% / 22.6% / 28.1%
2412: 10.23M / 12.78M / -20.0% / -22.9% / -6.1%
2409: 10.9M / 12.09M / -9.8% / -36.6% / -6.0%
2406: 11.6M / 10.46M / 10.9% / -41.7% / 8.5%
2403: 10.69M / -- / -- / -52.0% / -19.4%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.0 / -0.06 / 100.0% / 100.0% / 100.0%
2412: -0.06 / -0.08 / 25.0% / -- / 0.0%
2409: -0.06 / -0.08 / 25.0% / -166.7% / -100.0%
2406: -0.03 / -0.16 / 81.2% / -137.5% / 70.0%
2403: -0.1 / -- / -- / -132.3% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 72.63M(24.9%) / --(--)
2212: 58.14M(47.6%) / -0.6(-39.5%)
2112: 39.39M(28.7%) / -0.43(40.3%)
2012: 30.59M(--) / -0.72(-1128.6%)

#TACT

- 사업요약: TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. It of...